A holding company whose principal activity is undertaken in relation to the commercialization of its Parsortix cell separation system, with deployment in non-invasive cancer diagnostics.
Standard Tech Screen Qualifier
Latest Commentary – 29-Jul-2018 – 55p – £64.4m – PER n/a
After being flat in 2018A, Revenue growth is now forecast to double in each of the next 3 years (2019E, 2020E & 2021E) but respective EPS forecasts are -6.3p, -6.1p & -4.2p. Having never made a Profit and not even forecast to do so, it’s hard to make an investment case here at present.